Celldex (CLDX) Prices 13.378M Share Common Offering at $9.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- NVIDIA reports 9.3% passive stake in Nebius
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock
June 15, 2020 10:35 PM EDTHAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.001 per share, at a price to the public of $9.75 per share. In connection with the offering, Celldex has also granted the underwriter a 30-day option to purchase up to an additional 2,006,688 shares of common stock offered in the public offering, at the same public offering price per share less underwriting discounts and commissions.
Cantor Fitzgerald &... More
